{"id":"f14c78c2-9a4b-53ed-8841-d1dad0fd6f04","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:oral-nattokinase-lowers-infarct-volume-after-experimental-stroke","predicate":"reduces","statement":"Nattokinase given by mouth for seven days before middle cerebral artery occlusion dose-dependently reduced infarct volume.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"e6b00651-4fd9-5c73-9007-f8f49d8592cc","mechanism_event_label":"Nattokinase given by mouth for seven days before middle cerebral artery occlusion dose-dependently reduced infarct volume.","subject":{"id":"6b03a125-209a-5060-8b35-ec9e0e54033c","slug":"nattokinase","display_name":"Nattokinase / subtilisin NAT","entity_type_key":"peptide"},"object":{"id":"5a5027c1-4990-572d-b76a-0d01c3237a93","slug":"rat-cerebral-infarct-volume","display_name":"Cerebral infarct volume after transient middle cerebral artery occlusion in rat","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e6b00651-4fd9-5c73-9007-f8f49d8592cc","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:oral-nattokinase-lowers-infarct-volume-after-experimental-stroke-event","event_type":"observed_intervention","label":"Nattokinase given by mouth for seven days before middle cerebral artery occlusion dose-dependently reduced infarct volume.","description":"Brain, transient middle cerebral artery occlusion","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6b03a125-209a-5060-8b35-ec9e0e54033c","slug":"nattokinase","display_name":"Nattokinase / subtilisin NAT","entity_type_key":"peptide"},"role":"acting component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"5a5027c1-4990-572d-b76a-0d01c3237a93","slug":"rat-cerebral-infarct-volume","display_name":"Cerebral infarct volume after transient middle cerebral artery occlusion in rat","entity_type_key":"cellular_process"},"role":"component the finding is about","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"7 days of pre-treatment","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Rat","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Nattokinase 65 or 130 mg/kg","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Pre-treatment, not treatment: the enzyme was on board before the insult, which is not how an acute stroke is treated. High doses on a body-weight basis. No human clinical inference follows.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Rat","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Nattokinase given by mouth for seven days before middle cerebral artery occlusion dose-dependently reduced infarct volume.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Nattokinase Attenuates Acute Cerebral Infarction in a Rat Model of Middle Cerebral Artery Occlusion. (2026) https://pubmed.ncbi.nlm.nih.gov/41760340/ DOI: 10.21873/invivo.14243","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vivo, oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Brain, transient middle cerebral artery occlusion","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"55f22aad-d19c-587b-975a-e91a7fbe2e83","evidence_kind":"source_excerpt","locator":"Lines 1291-1291","start_line":1291,"end_line":1291,"excerpt":"Nattokinase given by mouth for seven days before middle cerebral artery occlusion dose-dependently reduced infarct volume.","model_system":"Rat","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"41cb127c-1c23-53aa-b7d0-5ec7f6fa3c99","stable_key":"import-33bef151-bdc7-5892-aff6-0345ab149739","title":"Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23)","document_type":"imported_text","citation_label":"Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text.","file_path":"","sha256":"34fc46e0e849d06bfa13cb099a79b50679dd6fd0de8a5a0575326afdde3259c1","revision_id":"efd063e6-e982-5f6e-a4b8-6f2ffe4185ce","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}